The Promise of Genomics
Pharmaceutical Executive
During the next three years, an estimated $38 billion in brand-name pharmaceuticals will come off patent, leaving a financial void that many pharma companies hope to fill with functional genomics.
During the next three years, an estimated $38 billion in brand-name pharmaceuticals will come off patent, leaving a financial void that many pharma companies hope to fill with functional genomics.
This relatively new field of genome-wide analysis, which seeks to determine gene function, includes microarray technology, non-array gene expression, transgenic animals, and downregulation reagents. A report from Front Line says functional genomics will be a $524 million industry by 2007, with Applied Biosystems and Gene Logic as probable front-runners.
The current market leader, Affymetrix, represents 25 percent of the industry with its oligonucleotide array technology. Yet, Front Line estimates that by 2007 microarray manufacturers will move to the back of the pack as more gene profiles are documented, leaving companies with good drug target validation accuracy in the front.
As functional genomics grows, one likely dilemma is the compatibility of data between software platforms. Widespread adoption of functional genomic technology may have to wait until analysis techniques and data archiving systems are standardized.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Beyond the Prescription: The Role Pharma Plays in Digital Health Conversations
April 1st 2025As social media continues to influence healthcare communication, it presents both challenges and opportunities for the pharmaceutical industry. In this interview, Jennifer Harakal of Canopy Life Sciences discusses balancing compliance with effective digital engagement to build trust and facilitate meaningful healthcare conversations.
